Sacituzumab Govitecan

MADRID — Sacituzumab govitecan as a second-line treatment for extensive stage small cell lung cancer showed promising antitumor activity and had manageable safety, according to research presented at ESMO Congress.

Healio spoke with Eleonora Teplinsky, MD, about new treatment options available to patients with breast cancer.

Healio spoke with Sara M. Tolaney, MD, MPH, about recent advancements in metastatic breast cancer.

Healio spoke with Nancy U. Lin, MD, about metastatic breast cancer, touching on approvals, agents in the pipeline, surveillance, survivorship and other topics impacting clinicians and patients.

CHICAGO — Sacituzumab govitecan continued to show significant improvement in OS among patients with heavily pretreated metastatic hormone receptor-positive breast cancer, according to final OS results of the phase 3 TROPiCS-02 study.

Healio spoke with Ahmed Elkhanany, MD, about treatment options available in metastatic triple-negative breast cancer.

Healio spoke with Ahmed Elkhanany, MD, about recent advancements in metastatic triple-negative breast cancer.

SAN FRANCISCO — Sacituzumab govitecan induced response among one-third of platinum-ineligible patients with metastatic urothelial carcinoma whose disease progressed after checkpoint inhibitor therapy, according to study results.

The FDA expanded the approval of sacituzumab govitecan-hziy to include treatment of certain patients with hormone receptor-positive disease.

SAN ANTONIO — Sacituzumab govitecan prolonged survival compared with physician’s choice of therapy among patients with heavily pretreated breast cancer, according to results presented at San Antonio Breast Cancer Symposium.